Abstract
Background:Activating epidermal growth factor receptor (EGFR) mutations have been implicated in non-small cell lung cancer (NSCLC), and have also been clinically correlated with patient sensitivity to targeted EGFR inhibitors.Aim:To describe...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have